Prothena | PRTA - Interest Expense On Debt

Stock Price
9.03
Daily Change
0.01 0.11%
Monthly
-9.15%
Yearly
-40.71%
Q1 Forecast
8.74

Prothena reported $352.63M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Akebia Therapeutics 364.15M 18.56M Sep/2025
ALKERMES USD 4.65M 1.35M Dec/2024
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
Amgen USD 653M 32M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.58M 100K Sep/2025
Exelixis USD 23.4M 3.9M Sep/2023
Immunic 400K 400K Dec/2024
Incyte USD 582K 10K Dec/2025
Ionis Pharmaceuticals USD 18M 1000K Sep/2025
MacroGenics USD 3.34M 2.54M Sep/2025
Nektar Therapeutics USD 6.02M 420K Sep/2024
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Prothena USD 352.63M 46.44M Sep/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Ultragenyx Pharmaceutical USD 19M 4.85M Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025
Xoma USD 3.4M 150K Jun/2024